Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Atopic dermatitis (AD) is a common chronic skin condition with a worldwide prevalence of 1 to 20% in adults, approximately 20% of patients have moderate-to-severe disease [1–4]. It is characterized by the T-helper (Th)-2-mediated skin inflammation, epidermal barrier dysfunction and increased Staphylococcus aureus colonization [5,6]. Despite the high prevalence of AD, treatments are limited, especially for patients with moderate to severe disease, only 3 (depending on country) systemic therapeutic options approved for patients with severe disease who are not controlled by topical medications, including oral corticosteroids, oral cyclosporin, and UVA/narrow-band UVB phototherapy [7].